Carboplatin AUC Dose Calculator — Calvert Formula with GFR Capping

How to Use This Calculator

1. Enter target AUC (typically 4-6) and patient GFR in mL/min.
2. Carboplatin dose in mg calculates instantly using Calvert formula with FDA GFR cap at 125 mL/min.
3. Use the GFR Methods tab to estimate GFR from Cockcroft-Gault or CKD-EPI.
4. Use the AUC by Indication tab to identify the appropriate target AUC for your clinical setting.

Formula

Example

Frequently Asked Questions

• What is the Calvert formula for carboplatin? ▼
  The Calvert formula is the standard pharmacokinetic method for calculating carboplatin dose, based on the drug's relationship with renal clearance. Published by Calvert et al. in the Journal of Clinical Oncology in 1989, the formula is: Carboplatin dose (mg) = Target AUC (mg/mL·min) × [GFR (mL/min) + 25]. The target AUC represents the desired drug exposure — the area under the plasma concentration-time curve — and is selected based on the treatment indication, combination regimen, and patient-specific factors. The 25 added to GFR represents non-renal carboplatin clearance, which is relatively constant across patients. Unlike most cytotoxics that are dosed per BSA, carboplatin is dosed by AUC because its haematological toxicity (primarily thrombocytopenia and neutropenia) correlates much more closely with plasma AUC than with BSA. This makes the Calvert formula genuinely pharmacokinetically rational — a rare feature in oncology dosing. The formula was derived from a population of ovarian cancer patients and has been prospectively validated across multiple tumour types and patient populations.
• Why is GFR capped at 125 mL/min in the Calvert formula? ▼
  The FDA issued a safety communication in 2010 recommending that GFR be capped at 125 mL/min when calculating carboplatin doses using the Calvert formula, following post-marketing reports of fatal carboplatin overdoses. The problem arose because some laboratories began reporting GFR estimates based on the Cockcroft-Gault formula using actual body weight — rather than ideal or adjusted weight — in obese patients. Combined with the then-common practice of not applying a GFR cap, this resulted in GFR values well above 125 mL/min in large, obese patients, which yielded carboplatin doses substantially higher than intended. The FDA cap prevents carboplatin from being overdosed in patients whose estimated GFR may be unrealistically high due to muscle mass, body habitus, or measurement methodology. Patients with a truly very high measured GFR (e.g., a young athletic patient with a measured 51Cr-EDTA GFR of 150 mL/min) would theoretically be underdosed by the cap — but in clinical oncology practice, such patients are uncommon. The cap is now standard across most institutional protocols and electronic prescribing systems.
• What target AUC is used for different indications? ▼
  Target AUC for carboplatin is indication-specific and protocol-dependent. For first-line ovarian cancer, the standard is AUC 5–6 in combination with paclitaxel 175 mg/m² every 3 weeks (GOG-158, ICON3 trials). For recurrent platinum-sensitive ovarian cancer, AUC 4–5 is used with gemcitabine (ICON4) or liposomal doxorubicin. For good-risk testicular germ cell tumours as an alternative to BEP, AUC 5–7 is used based on Medical Research Council trials. For NSCLC (non-small cell lung cancer), carboplatin AUC 5–6 is paired with paclitaxel 200 mg/m² every 3 weeks, or AUC 5–6 with pemetrexed for non-squamous NSCLC. Weekly dose-dense protocols typically use AUC 1.5–2 per week. Lower AUC targets (2–4) are used when carboplatin is combined with particularly myelosuppressive agents (gemcitabine, etoposide) or in patients with reduced marrow reserve. The appropriate AUC should always be verified against current NCCN guidelines or the specific trial protocol, as dosing standards evolve with publication of new trial data.
• Why is carboplatin dosed by AUC rather than by BSA like most other chemotherapy? ▼
  Carboplatin is uniquely dosed by AUC because its pharmacokinetics are unusually predictable from renal function, and its toxicity directly correlates with plasma AUC rather than BSA. This distinction stems from carboplatin's predominant renal elimination — approximately 60–70% of carboplatin is excreted unchanged in the urine — meaning patients with higher GFR clear the drug faster and require higher doses to achieve equivalent AUC. If carboplatin were dosed by BSA like paclitaxel or doxorubicin, patients with high GFR (such as young patients or those well-hydrated) would receive insufficient drug and be underdosed, while patients with renal impairment would be overdosed and risk severe thrombocytopenia and haematological toxicity. The Calvert formula corrects for this by directly incorporating GFR into the dose calculation. Multiple clinical studies have confirmed that AUC-based dosing achieves more consistent haematological toxicity rates and drug exposure compared to BSA-based dosing for carboplatin. This pharmacokinetic approach is now considered the gold standard for carboplatin and has influenced how other renally cleared drugs are dosed in oncology.
• How does carboplatin differ from cisplatin in terms of dosing and toxicity? ▼
  Carboplatin and cisplatin are both platinum-based alkylating agents that work by forming intra- and inter-strand DNA crosslinks, but they differ substantially in pharmacokinetics, toxicity profile, and dosing. Cisplatin is dosed by BSA (mg/m²) and is primarily renally excreted as intact drug, making it directly nephrotoxic — aggressive intravenous hydration (1–2 L of normal saline before and after administration) is mandatory to prevent cisplatin-induced nephrotoxicity. Cisplatin causes significantly more nausea and vomiting (among the most emetogenic chemotherapy agents), peripheral neuropathy, and ototoxicity than carboplatin. Carboplatin is dosed by AUC using the Calvert formula, is less nephrotoxic, less emetogenic, and causes less neuropathy. However, carboplatin causes substantially more haematological toxicity than cisplatin — particularly thrombocytopenia, which is the dose-limiting toxicity. In terms of efficacy, carboplatin and cisplatin are considered broadly equivalent in most solid tumour settings (ovarian, NSCLC, head and neck), with meta-analyses showing similar overall survival outcomes. Cisplatin retains superiority in certain germ cell tumour settings and in some squamous cell carcinomas. Carboplatin is generally preferred in older adults, patients with pre-existing renal dysfunction or neuropathy, and settings where quality-of-life and outpatient tolerability are priorities.

Related Calculators